论文信息 - Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study - 字舞流文

Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study

J. Ahn | K. Tamura | B. V. Van Tine | K. Horibe | W. Edenfield | T. Kim | F. Braiteh | Yuankai Shi | C. Gambacorti-Passerini | P. Selaru | Li Zhang | J. Paolini | J. Beck | T. Esaki | S. Orlov | Shang-Ju Wu | Huiqiang Huang | Matthew H. Taylor